Abstract:Background: Clinically, neuropathic pain is a severe side effect of oxaliplatin chemotherapy, which usually leads to dose reduction or cessation of treatment. Due to the unawareness of detailed mechanisms of oxaliplatin-induced neuropathic pain, it is difficult to develop an effective therapy and limits its clinical use. Objectives: The aim of the present study was to identify the role of sirtuin 1 (SIRT1) reduction in epigenetic regulation of the expression of voltage-gated sodium channels 1.7 (Nav1.7) in the dorsal root ganglion (DRG) during oxaliplatin-induced neuropathic pain. Study design: Controlled animal study. Setting: University laboratory. Methods: The von Frey test was performed to evaluate pain behavior in rats. Real-time quantitative polymerase chain reaction, western blotting, electrophysiological recording, chromatin immunoprecipitation, and small interfering RNA (siRNA) were used to illustrate the mechanisms. Results: In the present study, we found that both the activity and expression of SIRT1 were significantly decreased in rat DRG following oxaliplatin treatment. The activator of SIRT1, resveratrol, not only increased the activity and expression of SIRT1, but also attenuated the mechanical allodynia following oxaliplatin treatment. In addition, local knockdown of SIRT1 by intrathecal injection of SIRT1 siRNA caused mechanical allodynia in naive rats. Besides, oxaliplatin treatment enhanced the action potential firing frequency of DRG neurons and the expression of Nav1.7 in DRG and activation of SIRT1 by resveratrol reversed this effect. Furthermore, blocking Nav1.7 by ProTx II (a selective Nav1.7 channel blocker) reversed oxaliplatin-induced mechanical allodynia. In addition, histone H3 hyperacetylation at the Nav1.7 promoter in DRG of rats following oxaliplatin treatment was significantly suppressed by activation of SIRT1 with resveratrol. Moreover, both the expression of Nav1.7 and histone H3 acetylation at the Nav1.7 promoter were upregulated in the DRG by local knockdown of SIRT1 with SIRT1 siRNA in naive rats. Limitations: More underlying mechanism(s) of SIRT1 reduction after oxaliplatin treatment needs to be explored in future research. Conclusions: These findings suggest that reduction of SIRT1-mediated epigenetic upregulation of Nav1.7 in the DRG contributes to the development of oxaliplatin-induced neuropathic pain in rats. The intrathecal drug delivery treatment of activating SIRT1 might be a novel therapeutic option for oxaliplatin-induced neuropathic pain.

Tat-HA-NR2B9c Attenuate Oxaliplatin-Induced Neuropathic Pain.

NFATc2-dependent Epigenetic Downregulation of the TSC2/Beclin-1 Pathway is Involved in Neuropathic Pain Induced by Oxaliplatin

Downregulation of Metallothionein-2 Contributes to Oxaliplatin-Induced Neuropathic Pain

HCN2 Contributes to Oxaliplatin-Induced Neuropathic Pain by Inducing Spinal Long-Term Potentiation Via Activation of NMDA Receptor-Mediated CaMKII Signaling

Engagement of MicroRNA-155 in Exaggerated Oxidative Stress Signal and TRPA1 in the Dorsal Horn of the Spinal Cord and Neuropathic Pain During Chemotherapeutic Oxaliplatin

Tetrandrine alleviates oxaliplatin-induced mechanical allodynia via modulation of inflammation-related genes

Behavioral and Immunohistological Assessment of Painful Neuropathy Induced by a Single Oxaliplatin Injection in the Rat

Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat.

The α9α10 Nicotinic Acetylcholine Receptor Antagonist αO-Conotoxin GeXIVA[1,2] Alleviates and Reverses Chemotherapy-Induced Neuropathic Pain

L type Ca²+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats

2-Bromopalmitate decreases spinal inflammation and attenuates oxaliplatin-induced neuropathic pain via reducing Drp1-mediated mitochondrial dysfunction

Curcumin Alleviates Oxaliplatin-Induced Peripheral Neuropathic Pain Through Inhibiting Oxidative Stress-Mediated Activation of NF-κB and Mitigating Inflammation.

Reduction of SIRT1-Mediated Epigenetic Upregulation of Nav1.7 Contributes to Oxaliplatin-Induced Neuropathic Pain

Sodium Butyrate Restored TRESK Current Controlling Neuronal Hyperexcitability in a Mouse Model of Oxaliplatin-Induced Peripheral Neuropathic Pain

Huangqi Guizhi Wuwu Decoction Can Prevent and Treat Oxaliplatin Induced Neuropathic Pain by TNFα/IL-1β/IL-6/MAPK/NF-kB Pathway

L-Tetrahydropalmatine Reduces Oxaliplatin Accumulation In The Dorsal Root Ganglion And Mitochondria Through Selectively Inhibiting The Transporter-Mediated Uptake Thereby Attenuates Peripheral Neurotoxicity

Pharmacological and Computational Evaluation of an Isoxazolone Derivative for Mitigating Cisplatin-Induced Neuropathic Pain

Oxaliplatin-induced changes in expression of transient receptor potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity

HCN2 contributes to oxaliplatin-induced neuropathic pain through activation of the CaMKII/CREB cascade in spinal neurons.

Effects of Antidepressant Agents on the Neuropathic Pain Induced by Oxaliplatin

The inhibition of spinal synaptic plasticity mediated by activation of AMP-activated protein kinase signaling alleviates the acute pain induced by oxaliplatin